美托洛尔对感染性休克合并心肌损伤患者临床预后的影响

池锐彬, 邹启明, 李超锋, 等. 美托洛尔对感染性休克合并心肌损伤患者临床预后的影响[J]. 临床急诊杂志, 2019, 20(7): 572-575. doi: 10.13201/j.issn.1009-5918.2019.07.016
引用本文: 池锐彬, 邹启明, 李超锋, 等. 美托洛尔对感染性休克合并心肌损伤患者临床预后的影响[J]. 临床急诊杂志, 2019, 20(7): 572-575. doi: 10.13201/j.issn.1009-5918.2019.07.016
CHI Ruibin, ZHOU Qiming, LI Chaofeng, et al. Influence of metoprolol on clinical prognosis in septic shock patients with myocardial injury[J]. J Clin Emerg, 2019, 20(7): 572-575. doi: 10.13201/j.issn.1009-5918.2019.07.016
Citation: CHI Ruibin, ZHOU Qiming, LI Chaofeng, et al. Influence of metoprolol on clinical prognosis in septic shock patients with myocardial injury[J]. J Clin Emerg, 2019, 20(7): 572-575. doi: 10.13201/j.issn.1009-5918.2019.07.016

美托洛尔对感染性休克合并心肌损伤患者临床预后的影响

  • 基金项目:

    中山市医学科研项目(No:2014A020182)

详细信息
    通讯作者: 池锐彬,E-mail:CRB77970922@163.com
  • 中图分类号: R459.7

Influence of metoprolol on clinical prognosis in septic shock patients with myocardial injury

More Information
  • 目的: 分析感染性休克早期合并心肌损伤患者的临床预后情况,初步探讨美托洛尔对其临床预后的影响。方法: 回顾分析2014-03—2017-07期间在我院ICU住院的42例感染性休克合并心肌损伤患者的临床资料及预后情况,根据治疗初期是否使用美托洛尔治疗分为美托洛尔组和非美托洛尔组,比较两组患者的一般资料、感染来源、临床预后、心脏标志物、住院病死率及28d病死率。根据临床预后情况分为28d死亡组和28d存活组,比较两组间患者救治初期的临床危重度、心脏标志物以及美托洛尔使用情况等。结果: ①整个研究人群住院病死率为28.5%,28d病死率为35.7%。美托洛尔组的住院病死率和28d病死率(分别为22.7%和35.0%)低于非美托洛尔组(分别为27.3%和45.0%),但差异无统计学意义(P>0.05)。②28d死亡组的APACHEⅡ评分、N端脑钠肽前体(NT-pro-BNP)及高敏肌钙蛋白T(cTNT)均明显高于28d存活组[分别为(28±5)vs.(21±3)分,(1760±370)vs.(1250±230)pg/ml和(323±75)vs.(228±56)pg/ml],差异有统计学意义(P<0.05)。③与28d死亡组比较,28d存活组在初始治疗中采用美托洛尔方案的患者数更多,差异有统计学意义(P<0.05)。结论: 感染性休克合并心肌损伤患者病情危重,NT-proBNP、cTNT水平明显升高者预后更差,美托洛尔可能降低其住院病死率和28d病死率。
  • 加载中
  • [1]

    李振华,董磊,王国兴,等.脑利钠肽、肌钙蛋白T和I监测对重症脓毒症和脓毒症休克预后的意义[J].中华急诊医学杂志,2012,21(9):1016-1021.

    [2]

    庄海舟,沈潞华.脓毒症时心肌损伤发生机制研究进展[J].实用医学杂志,2008,24(24):4313-4315.

    [3]

    Esper AM,Martin GS.Extending international sepsis epidemiology:the impact of organ dysfunction[J].Crit Care,2009,13(1):120.

    [4]

    Aboab J,Sebille V,Jourdain M,et al.Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock[J].Int Care Med,2011,37(8):1344-1351.

    [5]

    Morelli A,Ertmer C,Westphal M,et al.Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock:a randomized clinical trial[J].JAMA,2013,310(16):1683-1691.

    [6]

    Dellinger RP,Levy MM,Rhodes A,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock:2012[J].Crit Care Med,2013,41(2):580-637.

    [7]

    严静,李莉.脓毒症心肌损伤与血流动力学[J].医学新知杂志,2012,22(1):1-3,8.

    [8]

    Jozwiak M,Persichini R,Monnet X,et al.Management of myocardial dysfunction in severe sepsis[J].Semin Respir Crit Care Med,2011,32(2):206-214.

    [9]

    池锐彬,林婷,周卉芬,等.感染性休克早期心肌损伤患者应用β受体阻滞剂的安全性探讨[J].内科急危重症杂志,2016,22(1):48-50.

    [10]

    Guest TM,Ramanathan JH,Tuteur PG,et al.Myocardial injury in critically ill patients[J].JAMA,1995,273(24):1945.

    [11]

    Turner A,Tsamitros M,Bellomo R,et al.Myocardial cell injury in septic shock[J].Crit Care Med,1999,27(9):2035-2036.

    [12]

    McLean AS,Huang SJ,Nalos M,et al.The confounding effects of age,gender,serum creatinine,and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients[J].Crit Care Med,2003,31(11):2611-2618.

    [13]

    Favory R,Neviere R.Significance and interpretation of elevated troponin in septic patients[J].Crit Care,2006,10(4):224.

    [14]

    Novotnv NM,Lahm T,Markel TA,et al.Beta blockers in sepsis:reexamining the evidence[J].Shock,2009,31:113-119.

    [15]

    Parker MM,Shelhamcr JH,Natansen C,et al.Serial cardiovascular variables in survivors and nonsurvivors of human septic shock:heart rate an early predictor of prognosis[J].Crit Care Med,1987,15(10):923-929.

    [16]

    池锐彬,雷玲,简志刚,等.美托洛尔对感染性休克早期心肌损伤患者血流动力学的影响[J].中国呼吸与危重监护杂志,2016,15(1):53-56.

  • 加载中
计量
  • 文章访问数:  320
  • PDF下载数:  197
  • 施引文献:  0
出版历程
收稿日期:  2018-12-19

目录